Related Experiment Video

Updated: Jul 28, 2025

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

13.6K

First-Line Treatment for Intermediate and Poor Risk Advanced or Metastatic Clear Cell Renal Cell Carcinoma

Michael T Serzan1, Wenxin Xu1, Stephanie A Berg1

  • 1Department of Medical Oncology, Dana-Farber Cancer Institute, 44 Binney Street D1230, Boston, MA 02115, USA.

Hematology/Oncology Clinics of North America
|May 31, 2023
PubMed

Insights

Combination therapies with immune checkpoint blockers improve patient outcomes compared to sunitinib monotherapy for specific risk groups. Future trials will explore adaptive strategies, triplet therapies, and biomarkers for optimal upfront treatment selection.

Area of Science:

  • Oncology
  • Immunotherapy
  • Clinical Trials

Background:

  • Sunitinib monotherapy is a standard treatment for certain cancer types.
  • Immune checkpoint blockers (ICBs) have emerged as a promising therapeutic strategy.
  • Identifying optimal upfront treatment is crucial for improving patient survival.

Purpose of the Study:

  • To evaluate the efficacy of combination therapies versus sunitinib monotherapy.
  • To identify patient subgroups that benefit most from combination treatments.
  • To inform future clinical trial designs for upfront cancer therapy.

Main Methods:

  • Comparative analysis of combination therapies (ICBs) against sunitinib monotherapy.
  • Focus on intermediate and poor-risk patient subgroups.
  • Review of overall response rate, progression-free survival, and overall survival data.

Main Results:

  • Combination therapies demonstrated superior overall response rate compared to sunitinib.
  • Improved progression-free survival was observed with combination treatments.
  • Enhanced overall survival was noted in patients receiving combination therapy.

Conclusions:

  • Combination therapy with immune checkpoint blockers offers significant survival benefits over sunitinib monotherapy in intermediate and poor-risk patients.
  • Future research should focus on adaptive clinical trial designs, exploring triplet regimens, and identifying novel biomarkers.
  • Personalized treatment selection based on risk stratification and biomarkers is essential for optimizing cancer care.
Keywords:
Clear cell renal cell carcinomaIMDC intermediate and poor riskImmune checkpoint inhibitorsVascular endothelial growth factor receptor tyrosine kinase inhibitor

More Related Videos

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers12:22

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

33.7K
Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Published on: April 29, 2014

16.7K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
51
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
Continuous Renal Replacement Therapy01:30

Continuous Renal Replacement Therapy

Continuous Renal Replacement Therapy, also known as CRRT, is a procedural treatment for acute kidney injury (AKI) that gradually removes uremic toxins and fluids while maintaining acid-base balance and stabilizing electrolytes. It is particularly useful for hemodynamically unstable patients. Unlike intermittent hemodialysis, which is faster, CRRT provides a gentler approach over 24 hours, closely mimicking the function of natural kidneys. However, CRRT is not ideal for patients with...
56
Renal Drug Clearance: Overview01:06

Renal Drug Clearance: Overview

Renal clearance is a crucial parameter in pharmacokinetics that quantifies the rate at which the kidneys excrete a drug. It represents a constant fraction of the central volume of distribution containing the drug that the kidney eliminates per unit of time.
Renal clearance can be calculated using different methods. One approach is to divide the urinary drug excretion rate by the plasma drug concentration. This method directly measures renal clearance, indicating the kidneys' efficiency in...
256